Finanzen von Kymera Therapeutics Inc (KYMR)KYMRKymera Therapeutics Inc

Evaluating the bottom line, Kymera Therapeutics, Inc. maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -116.32%, while the net margin is -94.17%. These profitability ratios, combined with a Return on Equity (ROE) of -24.15%, provide a clear picture of how effectively KYMR converts its operational activities into shareholder value.

In the context of the broader market, KYMR competes directly with industry leaders such as TWST and CAI. With a market capitalization of $9.41B, it holds a significant position in the sector. When comparing efficiency, KYMR's gross margin of 100.00% stands against TWST's 52.76% and CAI's 68.10%. Such benchmarking helps identify whether Kymera Therapeutics, Inc. is trading at a premium or discount relative to its financial performance.

Kymera has shown significant revenue growth, with Q2 2026 revenue at $65 million, but continues to report substantial net losses, with a net income of -$61 million in Q2 2026.